These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11372955)

  • 1. Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story?
    Dahl OE; Bergqvist D; Cohen AT; Frostick SP; Hull RD
    Acta Orthop Scand; 2001 Apr; 72(2):199-204. PubMed ID: 11372955
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-molecular weight heparin as prophylaxis against thromboembolism after total hip replacement--is it worth the price?
    Persson BM
    Acta Orthop Scand; 2000 Apr; 71(2):215-6. PubMed ID: 10852334
    [No Abstract]   [Full Text] [Related]  

  • 3. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
    Raskob GE
    Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of venous thromboembolism using only low-molecular-weight heparin?
    White RH
    Am J Med; 2001 Aug; 111(2):159-60. PubMed ID: 11498072
    [No Abstract]   [Full Text] [Related]  

  • 5. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
    Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
    J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
    Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
    Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
    Schousboe JT; Brown GA
    J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost considerations surrounding current and future anticoagulant therapies.
    Fang MC; Minichiello T; Auerbach AD
    Cleve Clin J Med; 2005 Apr; 72 Suppl 1():S43-9. PubMed ID: 15853179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of low molecular weight heparin in total knee arthroplasty.
    Iobst CA; Friedman RJ
    Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective.
    Borris LC; Lassen MR
    Drugs; 1996; 52 Suppl 7():42-6. PubMed ID: 9042559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
    Steurer J
    Praxis (Bern 1994); 2014 Jun; 103(13):785-6. PubMed ID: 24938162
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now?
    Dahl OE
    Haemostasis; 2000; 30 Suppl 2():101-5; discussion 82-3. PubMed ID: 11251351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboprophylaxis with low-molecular-weight heparin: economic considerations.
    Mätzsch T
    Haemostasis; 2000; 30 Suppl 2():141-5; discussion 128-9. PubMed ID: 11251359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 19. Low molecular weight heparin, heparin, and warfarin.
    Raskob GE
    Curr Opin Hematol; 1995 Sep; 2(5):372-9. PubMed ID: 9372022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reviparin as prophylaxis for thromboembolism after leg injury and hip replacement.
    Doggrell SA
    Expert Opin Pharmacother; 2003 Feb; 4(2):285-8. PubMed ID: 12562318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.